Status:
RECRUITING
Effects of Antrodia Cinnamomea on the Hepatoma Patients After Transcatheter Hepatic Artery Chemoembolization
Lead Sponsor:
Taichung Tzu Chi Hospital
Conditions:
Hepatocellular Carcinoma
Transarterial Chemoembolization
Eligibility:
All Genders
20-80 years
Phase:
NA
Brief Summary
Effects of Antrodia cinnamomea on the hepatoma patients after Transcatheter hepatic artery chemoembolization
Detailed Description
Hepatocellular carcinoma (HCC) accounts for 7% of all cancers worldwide and is the most common, primary liver malignancy globally. It is the second leading cause of cancer-related mortality in Taiwan....
Eligibility Criteria
Inclusion
- Sign the informed consent form
- Aged between 20 and 80
- Child-Pugh score class A, B
- Serum bilirubin level ≤ 1.5 times the upper limit of normal, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels ≤ 2 times the upper limit of normal
Exclusion
- Unwillingness to sign the informed consent form
- Child-Pugh score class C
- Patients with main portal vein thrombosis
- Patients with diffuse liver tumors
- Those who are allergic to the contrast medium
- Those with abnormal coagulation function
- Those with severe dysfunction of brain, heart and lung
- Patients with severe renal dysfunction (except those receiving renal dialysis)
- Unable to cooperate
- Those with uncontrolled arrhythmia and unstable blood pressure
- Some patients with abnormal thyroid function
- Any other contraindications such as active gastrointestinal bleeding, refractory ascites, or severe portal hypertension
- Pregnant or lactating women
Key Trial Info
Start Date :
January 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT07178093
Start Date
January 1 2023
End Date
December 31 2025
Last Update
September 17 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Taichung Tzu-Chi Hospital
Taichung, Taiwan, Taiwan, 406